Publications
- New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting2008 | First Faculty of Medicine
- Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice2007 | First Faculty of Medicine
- Anti-tumour resistance in mice treated with HPMA-based doxorubicin conjugate containing human intravenous immunoglobulin +1Publication without faculty affiliation
- Treatment with polymer-based doxorubicin conjugate containing human immunoglobulin directed to long-lasting tumour protectionPublication without faculty affiliation
- Unmasking tumour for the immune system: HPMA-based copolymers with pH-controlled release of doxorubicin in anti-cancer therapyPublication without faculty affiliation
- Anti-tumour efficacy of the conjugate based on N-(2-hydroxypropyl)methacrilamide containing doxorubicin and normal human immunoglobulinPublication without faculty affiliation
- Long-lasting anti-tumour protection in mice induced by the treatment with HPMA polymer-bound doxorubicinPublication without faculty affiliation
- Immunostimulatory effect of HPMA-based polymeric conjugate in tumour treatmentPublication without faculty affiliation
- Polymer drug carriers based on HPMA copolymers enabling tumour targeting and pH-triggered activation of drugPublication without faculty affiliation
- HPMA-based polymeric conjugate of doxorubicin acting in concert with the host anti-tumour immunityPublication without faculty affiliation
Loading network view...
